MicroRNA response elements-regulated TRAIL expression shows specific survival-suppressing activity on bladder cancer

Journal of Experimental and Clinical Cancer Research

Volumn 32, Issue 1, 2013, Pages

  Zhao, Youguang ^a   Li, Ying ^a   Wang, Liang ^a   Yang, Hang ^a   Wang, Qingtang ^a   Qi, Haiyan ^b   Li, Shadan ^a   Zhou, Peng ^a   Liang, Ping ^a   Wang, Qiwu ^a   Li, Xiaowei ^a  

^a General Hospital of PLA Chengdu Military Area Command   (China)

^b QINGDAO MUNICIPAL HOSPITAL   (China)

Author keywords

Adenovirus; Bladder cancer; miRNA; Specificity; TRAIL

Indexed keywords

ADENOVIRUS VECTOR; MICRORNA; MICRORNA 1; MICRORNA 133; MICRORNA 218; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLADDER CARCINOMA; CANCER INHIBITION; CANCER SURGERY; CANCER SURVIVAL; CELL SPECIFICITY; CONTROLLED STUDY; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE CONSTRUCT; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MICRORNA RESPONSE ELEMENT; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; RNA STRUCTURE; TUMOR XENOGRAFT;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; CARCINOMA, TRANSITIONAL CELL; CELL SURVIVAL; FEMALE; GENETIC THERAPY; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; RESPONSE ELEMENTS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874218565     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-32-10     Document Type: Article

References (51)

1. Bladder cancer in 2010: how far have we come? Jacobs BL, Lee CT, Montie JE, CA Cancer J Clin 2010 60 4 244 272 10.3322/caac.20077 20566675
2. Molecular targeting and gene delivery in bladder cancer therapy. Voutsinas GE, Stravopodis DJ, J Buon 2009 14 Suppl 1 69 S78 19785072
3. AdCD40L immunogene therapy for bladder carcinoma-the first phase I/IIa trial. Malmstrom PU, Loskog AS, Lindqvist CA, Mangsbo SM, Fransson M, Wanders A, Gardmark T, Totterman TH, Clin Cancer Res 2010 16 12 3279 3287 10.1158/1078-0432.CCR-10-0385 20448220
4. Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas. Vardouli L, Lindqvist C, Vlahou K, Loskog AS, Eliopoulos AG, Cancer Gene Ther 2009 16 11 848 860 10.1038/cgt.2009.31 19461675
5. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH, Nat Med 1999 5 2 157 163 10.1038/5517 9930862
6. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, Scaffidi C, Bretz JD, Zhang M, Gentz R, Mann M, Krammer PH, Peter ME, Dixit VM, Cell 1996 85 6 817 827 10.1016/S0092-8674(00)81266-0 8681377
7. Increased antitumor capability of fiber-modified adenoviral vector armed with TRAIL against bladder cancers. Zhao Y, Li Y, Wang Q, Wang L, Yang H, Li M, Mol Cell Biochem 2011 353 1-2 93 99 21437625
8. Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells. Metwalli AR, Khanbolooki S, Jinesh G, Sundi D, Shah JB, Shrader M, Choi W, Lashinger LM, Chunduru S, McConkey DJ, McKinlay M, Kamat AM, Cancer Biol Ther 2010 10 9 885 892 10.4161/cbt.10.9.13237 20814238
9. Oxidative stress sensitizes bladder cancer cells to TRAIL mediated apoptosis by down-regulating anti-apoptotic proteins. White-Gilbertson SJ, Kasman L, McKillop J, Tirodkar T, Lu P, Voelkel-Johnson C, J Urol 2009 182 3 1178 1185 10.1016/j.juro.2009.05.005 19625063
10. Response of bladder carcinoma cells to TRAIL and antisense oligonucleotide, Bcl-2 or clusterin treatments. Sun B, Moibi JA, Mak A, Xiao Z, Roa W, Moore RB, J Urol 2009 181 3 1361 1371 10.1016/j.juro.2008.10.148 19157446
11. TRAIL-induced apoptosis and expression of death receptor TRAIL-R1 and TRAIL-R2 in bladder cancer cells. Szliszka E, Mazur B, Zydowicz G, Czuba ZP, Krol W, Folia Histochem Cytobiol 2009 47 4 579 585 20430723
12. Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression. Shrader M, Pino MS, Lashinger L, Bar-Eli M, Adam L, Dinney CP, McConkey DJ, Cancer Res 2007 67 4 1430 1435 10.1158/0008-5472.CAN-06-1224 17308080
13. Expression of TRAIL, DR4, and DR5 in bladder cancer: correlation with response to adjuvant therapy and implications of prognosis. Li Y, Jin X, Li J, Jin X, Yu J, Sun X, Chu Y, Xu C, Li X, Wang X, Kakehi Y, Wu X, Urology 2012 79 4 968 e967 968 e915
14. Antitumor effects of bladder cancer-specific adenovirus carrying E1A-androgen receptor in bladder cancer. Zhai Z, Wang Z, Fu S, Lu J, Wang F, Li R, Zhang H, Li S, Hou Z, Wang H, Rodriguez R, Gene Ther 2012 19 11 1065 1074 10.1038/gt.2011.180 22218302
15. Prostate stem cell antigen enhancer and uroplakin II promoter based bladder cancer targeted tissue-specific vector. Wang D, Wang Z, Tian J, He X, Chowdhury WH, Zhang X, Li S, Rodriguez R, Urol Oncol 2010 28 2 164 169 10.1016/j.urolonc.2008.02.002 18440837
16. Targeting gene expression of the mouse uroplakin II promoter to human bladder cells. Zhu H, Zhang ZA, Xu C, Huang G, Zeng X, Wei S, Zhang Z, Guo Y, Urol Res 2003 31 1 17 21 12624658
17. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Catto JW, Alcaraz A, Bjartell AS, De Vere WR, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L, Schlomm T, Visakorpi T, Eur Urol 2011 59 5 671 681 10.1016/j.eururo.2011.01.044 21296484
18. Novel molecular targets regulated by tumor suppressors microRNA-1 and microRNA-133a in bladder cancer. Yamasaki T, Yoshino H, Enokida H, Hidaka H, Chiyomaru T, Nohata N, Kinoshita T, Fuse M, Seki N, Nakagawa M, Int J Oncol 2012 40 6 1821 1830 22378464
19. Tumor suppressive microRNA-1 mediated novel apoptosis pathways through direct inhibition of splicing factor serine/arginine-rich 9 (SRSF9/SRp30c) in bladder cancer. Yoshino H, Enokida H, Chiyomaru T, Tatarano S, Hidaka H, Yamasaki T, Gotannda T, Tachiwada T, Nohata N, Yamane T, Seki N, Nakagawa M, Biochem Biophys Res Commun 2012 417 1 588 593 10.1016/j.bbrc.2011.12.011 22178073
20. The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. Yoshino H, Chiyomaru T, Enokida H, Kawakami K, Tatarano S, Nishiyama K, Nohata N, Seki N, Nakagawa M, Br J Cancer 2011 104 5 808 818 10.1038/bjc.2011.23 21304530
21. Functional role of LASP1 in cell viability and its regulation by microRNAs in bladder cancer. Chiyomaru T, Enokida H, Kawakami K, Tatarano S, Uchida Y, Kawahara K, Nishiyama K, Seki N, Nakagawa M, Urol Oncol 30 4 434 443
22. MicroRNA expression signatures of bladder cancer revealed by deep sequencing. Han Y, Chen J, Zhao X, Liang C, Wang Y, Sun L, Jiang Z, Zhang Z, Yang R, Chen J, Li Z, Tang A, Li X, Ye J, Guan Z, Gui Y, Cai Z, PLoS One 2011 6 3 18286 10.1371/journal.pone.0018286 21464941
23. Differential miRNA expression profiles in bladder urothelial carcinomas. Song T, Xia W, Shao N, Zhang X, Wang C, Wu Y, Dong J, Cai W, Li H, Asian Pac J Cancer Prev 2010 11 4 905 911 21133599
24. FGF-2 regulates cell proliferation, migration, and angiogenesis through an NDY1/KDM2B-miR-101-EZH2 pathway. Kottakis F, Polytarchou C, Foltopoulou P, Sanidas I, Kampranis SC, Tsichlis PN, Mol Cell 2011 43 2 285 298 10.1016/j.molcel.2011.06.020 21777817
25. The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Friedman JM, Liang G, Liu CC, Wolff EM, Tsai YC, Ye W, Zhou X, Jones PA, Cancer Res 2009 69 6 2623 2629 10.1158/0008-5472.CAN-08-3114 19258506
26. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. Baffa R, Fassan M, Volinia S, O'Hara B, Liu CG, Palazzo JP, Gardiman M, Rugge M, Gomella LG, Croce CM, Rosenberg A, J Pathol 2009 219 2 214 221 10.1002/path.2586 19593777
27. MicroRNA-125b suppresses the development of bladder cancer by targeting E2F3. Huang L, Luo J, Cai Q, Pan Q, Zeng H, Guo Z, Dong W, Huang J, Lin T, Int J Cancer 2011 128 8 1758 1769 10.1002/ijc.25509 20549700
28. MiR-133a induces apoptosis through direct regulation of GSTP1 in bladder cancer cell lines. Uchida Y, Chiyomaru T, Enokida H, Kawakami K, Tatarano S, Kawahara K, Nishiyama K, Seki N, Nakagawa M, Urol Oncol 2011 31 1 115 123 21396852
29. miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Chiyomaru T, Enokida H, Tatarano S, Kawahara K, Uchida Y, Nishiyama K, Fujimura L, Kikkawa N, Seki N, Nakagawa M, Br J Cancer 2010 102 5 883 891 10.1038/sj.bjc.6605570 20160723
30. Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Ichimi T, Enokida H, Okuno Y, Kunimoto R, Chiyomaru T, Kawamoto K, Kawahara K, Toki K, Kawakami K, Nishiyama K, Tsujimoto G, Nakagawa M, Seki N, Int J Cancer 2009 125 2 345 352 10.1002/ijc.24390 19378336
31. The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer. Villadsen SB, Bramsen JB, Ostenfeld MS, Wiklund ED, Fristrup N, Gao S, Hansen TB, Jensen TI, Borre M, Orntoft TF, Dyrskjot L, Kjems J, Br J Cancer 2012 106 2 366 374 10.1038/bjc.2011.520 22108519
32. Expression of miR-143 reduces growth and migration of human bladder carcinoma cells by targeting cyclooxygenase-2. Song T, Zhang X, Wang C, Wu Y, Dong J, Gao J, Cai W, Hong B, Asian Pac J Cancer Prev 2011 12 4 929 933 21790228
33. MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells. Noguchi S, Mori T, Hoshino Y, Maruo K, Yamada N, Kitade Y, Naoe T, Akao Y, Cancer Lett 2011 307 2 211 220 10.1016/j.canlet.2011.04.005 21550168
34. miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors. Ostenfeld MS, Bramsen JB, Lamy P, Villadsen SB, Fristrup N, Sorensen KD, Ulhoi B, Borre M, Kjems J, Dyrskjot L, Orntoft TF, Oncogene 2010 29 7 1073 1084 10.1038/onc.2009.395 19915607
35. MicroRNA-195-5p suppresses glucose uptake and proliferation of human bladder cancer T24 cells by regulating GLUT3 expression. Fei X, Qi M, Wu B, Song Y, Wang Y, Li T, FEBS Lett 2012 586 4 392 397 10.1016/j.febslet.2012.01.006 22265971
36. MicroRNA miR-199a-3p regulates cell proliferation and survival by targeting caveolin-2. Shatseva T, Lee DY, Deng Z, Yang BB, J Cell Sci 2011 124 Pt 16 2826 2836 21807947
37. Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Wiklund ED, Bramsen JB, Hulf T, Dyrskjot L, Ramanathan R, Hansen TB, Villadsen SB, Gao S, Ostenfeld MS, Borre M, Peter ME, Orntoft TF, Kjems J, Clark SJ, Int J Cancer 2011 128 6 1327 1334 10.1002/ijc.25461 20473948
38. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, Calin G, Wang H, Siefker-Radtke A, McConkey D, Bar-Eli M, Dinney C, Clin Cancer Res 2009 15 16 5060 5072 10.1158/1078-0432.CCR-08-2245 19671845
39. microRNA-203 suppresses bladder cancer development by repressing bcl-w expression. Bo J, Yang G, Huo K, Jiang H, Zhang L, Liu D, Huang Y, Febs J 2011 278 5 786 792 10.1111/j.1742-4658.2010.07997.x 21205209
40. Micro-RNA profiling in kidney and bladder cancers. Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, Bassi P, Sevignani C, Byrne D, Negrini M, Pagano F, Gomella LG, Croce CM, Baffa R, Urol Oncol 2007 25 5 387 392 10.1016/j.urolonc.2007.01.019 17826655
41. miR-218 on the genomic loss region of chromosome 4p15.31 functions as a tumor suppressor in bladder cancer. Tatarano S, Chiyomaru T, Kawakami K, Enokida H, Yoshino H, Hidaka H, Yamasaki T, Kawahara K, Nishiyama K, Seki N, Nakagawa M, Int J Oncol 2011 39 1 13 21 21519788
42. MicroRNA expression signatures of bladder cancer revealed by deep sequencing. Han Y, Chen J, Zhao X, Liang C, Wang Y, Sun L, Jiang Z, Zhang Z, Yang R, Chen J, Li Z, Tang A, Li X, Ye J, Guan Z, Gui Y, Cai Z, PLoS One 6 3 18286
43. Tumor suppressor microRNA-493 decreases cell motility and migration ability in human bladder cancer cells by downregulating RhoC and FZD4. Ueno K, Hirata H, Majid S, Yamamura S, Shahryari V, Tabatabai ZL, Hinoda Y, Dahiya R, Mol Cancer Ther 2012 11 1 244 253 10.1158/1535-7163.MCT-11-0592 22057916
44. Restoration of miR-517a expression induces cell apoptosis in bladder cancer cell lines. Yoshitomi T, Kawakami K, Enokida H, Chiyomaru T, Kagara I, Tatarano S, Yoshino H, Arimura H, Nishiyama K, Seki N, Nakagawa M, Oncol Rep 2011 25 6 1661 1668 21479368
45. Novel oncogenic function of mesoderm development candidate 1 and its regulation by MiR-574-3p in bladder cancer cell lines. Tatarano S, Chiyomaru T, Kawakami K, Enokida H, Yoshino H, Hidaka H, Nohata N, Yamasaki T, Gotanda T, Tachiwada T, Seki N, Nakagawa M, Int J Oncol 2012 40 4 951 959 22179486
46. MicroRNA-1826 targets VEGFC, beta-catenin (CTNNB1) and MEK1 (MAP2K1) in human bladder cancer. Hirata H, Hinoda Y, Ueno K, Shahryari V, Tabatabai ZL, Dahiya R, Carcinogenesis 2012 33 1 41 48 10.1093/carcin/bgr239 22049531
47. Immunocytochemical characterisation of cultures of human bladder mucosal cells. Woodman JR, Mansfield KJ, Lazzaro VA, Lynch W, Burcher E, Moore KH, BMC Urol 2011 11 5 10.1186/1471-2490-11-5 21496348
48. 5/35 fiber-modified conditionally replicative adenovirus armed with p53 shows increased tumor-suppressing capacity to breast cancer cells. He X, Liu J, Yang C, Su C, Zhou C, Zhang Q, Li L, Wu H, Liu X, Wu M, Qian Q, Hum Gene Ther 2011 22 3 283 292 10.1089/hum.2010.058 20846024
49. Precursor sequence, processing, and urothelium-specific expression of a major 15-kDa protein subunit of asymmetric unit membrane. Lin JH, Wu XR, Kreibich G, Sun TT, J Biol Chem 1994 269 3 1775 1784 7507484
50. Expression of miR-122 mediated by adenoviral vector induces apoptosis and cell cycle arrest of cancer cells. Ma L, Liu J, Shen J, Liu L, Wu J, Li W, Luo J, Chen Q, Qian C, Cancer Biol Ther 2010 9 7 554 561 10.4161/cbt.9.7.11267 20150764
51. Chimeric 5/35 adenovirus-mediated Dickkopf-1 overexpression suppressed tumorigenicity of CD44(+) gastric cancer cells via attenuating Wnt signaling. Wang B, Liu J, Ma LN, Xiao HL, Wang YZ, Li Y, Wang Z, Fan L, Lan C, Yang M, Hu L, Wei Y, Bian XW, Chen D, Wang J, J Gastroenterol 2012 Epub ahead of print